These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 34588467)
1. Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes. Bérard A; Strom S; Zhao JP; Kori S; Albrecht D Sci Rep; 2021 Sep; 11(1):19302. PubMed ID: 34588467 [TBL] [Abstract][Full Text] [Related]
2. Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes. Bérard A; Kori S Headache; 2012; 52(7):1085-93. PubMed ID: 22612391 [TBL] [Abstract][Full Text] [Related]
3. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Bérard A; Zhao JP; Shui I; Colilla S Ann Rheum Dis; 2018 Apr; 77(4):500-509. PubMed ID: 29222350 [TBL] [Abstract][Full Text] [Related]
4. Triptan safety during pregnancy: a Norwegian population registry study. Nezvalová-Henriksen K; Spigset O; Nordeng H Eur J Epidemiol; 2013 Sep; 28(9):759-69. PubMed ID: 23884894 [TBL] [Abstract][Full Text] [Related]
5. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Marchenko A; Etwel F; Olutunfese O; Nickel C; Koren G; Nulman I Headache; 2015 Apr; 55(4):490-501. PubMed ID: 25644494 [TBL] [Abstract][Full Text] [Related]
6. Available medications used as potential therapeutics for COVID-19: What are the known safety profiles in pregnancy. Bérard A; Sheehy O; Zhao JP; Vinet E; Quach C; Kassai B; Bernatsky S PLoS One; 2021; 16(5):e0251746. PubMed ID: 34010282 [TBL] [Abstract][Full Text] [Related]
7. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Spielmann K; Kayser A; Beck E; Meister R; Schaefer C Cephalalgia; 2018 May; 38(6):1081-1092. PubMed ID: 28758416 [TBL] [Abstract][Full Text] [Related]
8. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. Nezvalová-Henriksen K; Spigset O; Nordeng H Headache; 2010 Apr; 50(4):563-75. PubMed ID: 20132339 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452 [TBL] [Abstract][Full Text] [Related]
10. Prenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3-Year-Old Children: Results from the Norwegian Mother and Child Cohort Study. Wood ME; Lapane K; Frazier JA; Ystrom E; Mick EO; Nordeng H Paediatr Perinat Epidemiol; 2016 Mar; 30(2):190-200. PubMed ID: 26525300 [TBL] [Abstract][Full Text] [Related]
11. Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study. Yusuf A; Chia V; Xue F; Mikol DD; Bollinger L; Cangialose C Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1309-1315. PubMed ID: 30240072 [TBL] [Abstract][Full Text] [Related]
12. Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: Follow-up from the Norwegian Mother and Child Cohort Study. Harris GE; Wood M; Ystrom E; Nordeng H Paediatr Perinat Epidemiol; 2018 May; 32(3):247-255. PubMed ID: 29569251 [TBL] [Abstract][Full Text] [Related]
13. Prenatal triptan exposure and parent-reported early childhood neurodevelopmental outcomes: an application of propensity score calibration to adjust for unmeasured confounding by migraine severity. Wood ME; Frazier JA; Nordeng HM; Lapane KL Pharmacoepidemiol Drug Saf; 2016 May; 25(5):493-502. PubMed ID: 26554750 [TBL] [Abstract][Full Text] [Related]
14. Drugs for the acute treatment of migraine in children and adolescents. Richer L; Billinghurst L; Linsdell MA; Russell K; Vandermeer B; Crumley ET; Durec T; Klassen TP; Hartling L Cochrane Database Syst Rev; 2016 Apr; 4(4):CD005220. PubMed ID: 27091010 [TBL] [Abstract][Full Text] [Related]
15. Analysis of triptan use during pregnancy in Japan: A case series. Yamaguchi Y; Yamada T; Goto M; Kawasaki H; Wada T; Ikeda-Sakai Y; Saito Y; Hayashi M; Tanaka S; Takahashi R; Nakayama T; Murashima A; Kosugi S Congenit Anom (Kyoto); 2022 Mar; 62(2):78-81. PubMed ID: 34981573 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal changes in neurodevelopmental outcomes between 18 and 36 months in children with prenatal triptan exposure: findings from the Norwegian Mother and Child Cohort Study. Wood ME; Frazier JA; Nordeng HM; Lapane KL BMJ Open; 2016 Sep; 6(9):e011971. PubMed ID: 27625061 [TBL] [Abstract][Full Text] [Related]
17. Association Between Incident Exposure to Benzodiazepines in Early Pregnancy and Risk of Spontaneous Abortion. Sheehy O; Zhao JP; Bérard A JAMA Psychiatry; 2019 Sep; 76(9):948-957. PubMed ID: 31090881 [TBL] [Abstract][Full Text] [Related]
18. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. Djulus J; Koren G; Einarson TR; Wilton L; Shakir S; Diav-Citrin O; Kennedy D; Voyer Lavigne S; De Santis M; Einarson A J Clin Psychiatry; 2006 Aug; 67(8):1280-4. PubMed ID: 16965209 [TBL] [Abstract][Full Text] [Related]
19. [Migraines in pregnant patients: how safe are triptans?]. Vsc MMW Fortschr Med; 2015 Jun; 157(11):29. PubMed ID: 26049338 [No Abstract] [Full Text] [Related]
20. Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the antiretroviral pregnancy registry. Vannappagari V; Koram N; Albano J; Tilson H; Gee C J Acquir Immune Defic Syndr; 2015 Mar; 68(3):359-64. PubMed ID: 25469525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]